[go: up one dir, main page]

MY161552A - A polynucleotide and polypeptide sequence and methods thereof - Google Patents

A polynucleotide and polypeptide sequence and methods thereof

Info

Publication number
MY161552A
MY161552A MYPI2011004302A MYPI2011004302A MY161552A MY 161552 A MY161552 A MY 161552A MY PI2011004302 A MYPI2011004302 A MY PI2011004302A MY PI2011004302 A MYPI2011004302 A MY PI2011004302A MY 161552 A MY161552 A MY 161552A
Authority
MY
Malaysia
Prior art keywords
methods
present disclosure
polynucleotide
polypeptide sequence
precursor molecules
Prior art date
Application number
MYPI2011004302A
Inventor
Mulakkapurath Narayanan Manoj
Venkata Ramachandra Rao Vasamsetty
Madhuri Baliga
Kirubakaran Naveen Kumar
Chandrasekhar Bhaskaran Nair
Pillarisetti Venkata Subbarao
Original Assignee
Bigtec Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bigtec Private Ltd filed Critical Bigtec Private Ltd
Publication of MY161552A publication Critical patent/MY161552A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

THE PRESENT DISCLOSURE RELATES TO A FIELD OF RECOMBINANT DNA THERAPEUTICS. IT INVOLVES THE BIO-INFORMATICS DESIGN, SYNTHESIS OF ARTIFICIAL GENE FOR HUMAN INSULIN PRECURSOR INCLUDING LEADER PEPTIDE CODING SEQUENCE, CLONING IN AN EXPRESSION VECTOR AND EXPRESSION IN AN ORGANISM, PREFERABLY PICHIA PASTORIS. THE PRESENT DISCLOSURE ALSO RELATES TO METHODS OF DOWNSTREAM PROCESSING FOR OBTAINING PROTEIN PRECURSOR MOLECULES AND SUBSEQUENT CONVERSION OF PRECURSOR MOLECULES TO FUNCTIONAL PROTEINS.
MYPI2011004302A 2009-03-12 2010-03-12 A polynucleotide and polypeptide sequence and methods thereof MY161552A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN567CH2009 2009-03-12

Publications (1)

Publication Number Publication Date
MY161552A true MY161552A (en) 2017-04-28

Family

ID=42728894

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011004302A MY161552A (en) 2009-03-12 2010-03-12 A polynucleotide and polypeptide sequence and methods thereof

Country Status (11)

Country Link
US (3) US8575322B2 (en)
EP (1) EP2406377B1 (en)
KR (1) KR101702342B1 (en)
CN (1) CN102439154A (en)
AU (1) AU2010223154B2 (en)
BR (1) BRPI1008941A2 (en)
CA (1) CA2755300A1 (en)
MY (1) MY161552A (en)
SG (1) SG174313A1 (en)
WO (1) WO2010103546A2 (en)
ZA (1) ZA201107067B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9647999B2 (en) 2014-02-07 2017-05-09 Bank Of America Corporation Authentication level of function bucket based on circumstances
US9286450B2 (en) 2014-02-07 2016-03-15 Bank Of America Corporation Self-selected user access based on specific authentication types
US9223951B2 (en) 2014-02-07 2015-12-29 Bank Of America Corporation User authentication based on other applications
US9208301B2 (en) 2014-02-07 2015-12-08 Bank Of America Corporation Determining user authentication requirements based on the current location of the user in comparison to the users's normal boundary of location
US9721268B2 (en) 2014-03-04 2017-08-01 Bank Of America Corporation Providing offers associated with payment credentials authenticated in a specific digital wallet
US9729536B2 (en) 2015-10-30 2017-08-08 Bank Of America Corporation Tiered identification federated authentication network system
US10511692B2 (en) 2017-06-22 2019-12-17 Bank Of America Corporation Data transmission to a networked resource based on contextual information
US10524165B2 (en) 2017-06-22 2019-12-31 Bank Of America Corporation Dynamic utilization of alternative resources based on token association
US10313480B2 (en) 2017-06-22 2019-06-04 Bank Of America Corporation Data transmission between networked resources
TW201934752A (en) * 2018-02-09 2019-09-01 大陸商江蘇恆瑞醫藥股份有限公司 A codon optimized human insulin analogue precursor gene and a signal peptide gene
AU2019272401A1 (en) * 2018-05-24 2021-01-14 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing precursor of recombinant human insulin or analogue thereof
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK463887D0 (en) * 1987-09-07 1987-09-07 Novo Industri As GAERLEADER
DK105489D0 (en) * 1989-03-03 1989-03-03 Novo Nordisk As POLYPEPTIDE
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
KR20010034305A (en) 1998-01-23 2001-04-25 한센 핀 베네드 Process for making desired polypeptides in yeast
FR2810339B1 (en) * 2000-06-14 2004-12-10 Hoechst Marion Roussel Inc COMBINATORIAL BANKS IMPROVED BY RECOMBINATION IN YEAST AND METHOD OF ANALYSIS
DE112007003588A5 (en) * 2007-05-03 2010-04-15 Siemens Aktiengesellschaft Method for influencing devices of a high voltage installation
WO2008139496A1 (en) 2007-05-16 2008-11-20 Bigtec Private Limited Recombinant human insulin and a method thereof

Also Published As

Publication number Publication date
EP2406377B1 (en) 2016-01-06
US8575322B2 (en) 2013-11-05
US20140051842A1 (en) 2014-02-20
US20120077966A1 (en) 2012-03-29
SG174313A1 (en) 2011-10-28
KR101702342B1 (en) 2017-02-03
ZA201107067B (en) 2012-05-30
CA2755300A1 (en) 2010-09-16
WO2010103546A2 (en) 2010-09-16
KR20110132447A (en) 2011-12-07
US9309281B2 (en) 2016-04-12
BRPI1008941A2 (en) 2015-09-01
AU2010223154B2 (en) 2014-10-09
US9238674B2 (en) 2016-01-19
EP2406377A2 (en) 2012-01-18
US20140057318A1 (en) 2014-02-27
WO2010103546A3 (en) 2011-01-06
AU2010223154A1 (en) 2011-10-13
EP2406377A4 (en) 2012-12-26
CN102439154A (en) 2012-05-02

Similar Documents

Publication Publication Date Title
MY161552A (en) A polynucleotide and polypeptide sequence and methods thereof
MX362028B (en) Extended recombinant polypeptides and compositions comprising same.
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
CY1116099T1 (en) CANCER Fusion Protein
EA201290722A1 (en) RECOMBINANT PROTEIN EXENDIN-4 AND ITS ANALOGUE, METHOD OF THEIR PREPARATION AND USE
EA201101553A1 (en) POLYPEPTID, DEGRADING CARBOHYDRATES AND ITS APPLICATIONS
NZ603570A (en) Biological materials related to her3
EA201300058A1 (en) POLYPEPTIDE, OWNED BETA GLUCOSIDAL ACTIVITY AND ITS APPLICATION
MX2011012906A (en) Recombinant production of peptides.
MX2009013137A (en) Methods for selecting protease resistant polypeptides.
UA110599C2 (en) Peptide for Immunotherapy of Tumors, Including Neuronal Tumors and Tumors of the Brain
IN2012DN02981A (en)
IN2013MN02441A (en)
EP2589658A4 (en) PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
IN2014DN09815A (en)
RU2012123642A (en) INSULIN ANALOGUES CONTAINING CHLORINATED AMINO ACIDS
PH12014501363A1 (en) Anticancer fusion protein
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
FI20115870A0 (en) Neuroprotective cell penetrating peptides
EA201300057A1 (en) POLYPEPTIDE, possessing carbohydrate-degrading activity, and its application
MX2021002985A (en) Short-acting factor vii polypeptides.
MX2013001836A (en) Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc.
MX2020007929A (en) Codon optimized precursor gene and signal peptide gene of human insulin analogue.
EA201300059A1 (en) POLYPEPTID, possessing the activity of the Volvolenin, and its application